Anthony Barron is presenting on “Quantifying the benefits of personalised medicines to patients, society and healthcare systems.” Charles River Associates has conducted an evidencebased analysis on behalf of The European Federation of Pharmaceutical Industries and Associations (EFPIA) and the European Biopharmaceutical Enterprises (EBE), to characterise and quantify the benefits of personalised medicines to patients, society and healthcare systems. This study seeks to identify barriers and enablers to the development and adoption of PM in Europe and elaborate strategic recommendations for decisionmakers to overcome these barriers and incentivise the development and adoption of PM in Europe.
For more information on this event, click here.
CRA leading the way in analytics
In recent years, the adoption of advanced treatments in inflammatory bowel disease has evolved. Oral products have captured a significant share in ulcerative...